High-Dose Ifosfamide and Doxorubicin for Advanced Soft Tissue Sarcomas
Author Information
Author(s): A. López-Pousa, J. Martín, J. Montalar, R. de las Peñas, J. García del Muro, J. Cruz, J. Maurel, P. Escudero, A. Casado, J. M. Buesa
Primary Institution: Spanish Group for Research on Sarcomas (GEIS)
Hypothesis
To explore the tolerance and the activity of high-dose ifosfamide combined with doxorubicin in patients with soft tissue sarcomas.
Conclusion
The combination of doxorubicin and high-dose ifosfamide was tolerated by 71% of patients, but resulted in substantial toxicity.
Supporting Evidence
- 71% of patients tolerated at least 4 cycles of treatment.
- 54% of patients experienced febrile neutropenia.
- The overall activity rate was 42% among assessable patients.
Takeaway
Doctors tested a new treatment for a type of cancer, and while many patients could handle it, a lot of them got very sick.
Methodology
Patients received doxorubicin and ifosfamide, with the ifosfamide dose adjusted based on toxicity, over a series of cycles.
Limitations
The study had a high rate of toxicity leading to treatment abandonment and three toxic deaths.
Participant Demographics
{"total":71,"male":29,"female":42,"median_age":55,"age_range":"22-65"}
Statistical Information
Confidence Interval
95% CI, 32 to 58%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website